Previous 10 | Next 10 |
Cardiol Therapeutics ( NASDAQ: CRDL ) is trading ~9% higher premarket after the company said it had begun a Phase II study to test its therapy, CardiolRx ,in patients with recurrent pericarditis. Pericarditis is an inflammatory heart disease, which causes swelling and irritati...
The Cleveland Clinic and the Mayo Clinic Study Sites have been Initiated and are Eligible to Recruit Participants Initiation of Additional U.S. Cardiovascular Research Centers is Planned for Q1, 2023 Oakville, Ontario--(Newsfile Corp. - December 12, 2022) - Cardiol Therapeutics Inc. ( NASDA...
Oakville, Ontario--(Newsfile Corp. - November 14, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the ...
Results Demonstrate Significant Reduction in Pericardial Effusion and Thickness and Significant Suppression of Key Inflammatory Markers IL-1β and IL-6 Data Presented at The American Heart Association Scientific Sessions 2022 Oakville, Ontario--(Newsfile Corp. - November 7, 2022) ...
Cardiol Therapeutics ( NASDAQ: CRDL ) said it will discontinue its LANCER trial of CardiolRx for COVID-19 and will prioritize its phase 2 programs of CardiolRx for two heart diseases. CardiolRx is a pharmaceutically manufactured oral cannabidiol formulation. ...
Discontinues LANCER Trial due to Lack of Eligible Patients for Recruitment Cash Runway Now Extends into 2026 Oakville, Ontario--(Newsfile Corp. - October 25, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sci...
Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022 Oakville, Ontario--(Newsfile Corp. - October 3, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences compan...
Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for t...
RALEIGH, NC / ACCESSWIRE / September 27, 2022 / The 2 nd Annual MicroCap Rodeo Conference is going on the road and will take place at the Swissotel in Chicago on October 12 th - 13th, 2022, where 60+ SmallCap, MicroCap and NanoCap public companies will be presenting to a global investor au...
Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patients Oakville, Ontario--(Newsfile Corp. - August 3, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focus...
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Inc. Company Name:
CRDL Stock Symbol:
NASDAQ Market:
Cardiol Therapeutics Inc. Website:
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...
2024-06-26 06:30:06 ET B. Riley analyst issues BUY recommendation for CRDL on June 26, 2024 04:52AM ET. CRDL was trading at $2.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendations . ...
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...